{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T06:41:56Z","timestamp":1769323316874,"version":"3.49.0"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Monoclonal antibodies are successful biologics in treating a variety of diseases, including the prevention or treatment of viral infections. CL184 is a 1:1 combination of two human monoclonal IgG1 antibodies (CR57 and CR4098) against rabies virus, produced in the PER.C6 human cell line. The two antibodies are developed as replacements of human rabies immune globulin (HRIG) and equine rabies immune globulin (ERIG) in postexposure prophylaxis (PEP). The rapid fluorescent focus inhibition test (RFFIT) is a cell-based virus neutralization assay which is usually performed to determine the biological potency of a vaccine and to measure the levels of protection against rabies in humans and animals. In order to confirm the suitability of this assay as a pharmacodynamic assay, we conducted a validation using both HRIG- and CL184-spiked serum samples and sera from vaccinated donors. The validation results met all analytical acceptance criteria and showed that HRIG and CL184 serum concentrations can be compared. Stability experiments showed that serum samples were stable in various suboptimal conditions but that rabies virus should be handled swiftly once thawed. We concluded that the assay is suitable for the measurement of polyclonal and monoclonal rabies neutralizing antibodies in clinical serum samples.<\/jats:p>","DOI":"10.1128\/aac.06179-11","type":"journal-article","created":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T02:53:11Z","timestamp":1335840791000},"page":"3524-3530","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":42,"title":["Validation of the Rapid Fluorescent Focus Inhibition Test for Rabies Virus-Neutralizing Antibodies in Clinical Samples"],"prefix":"10.1128","volume":"56","author":[{"given":"Stefan","family":"Kostense","sequence":"first","affiliation":[{"name":"Crucell Holland B.V., Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Moore","sequence":"additional","affiliation":[{"name":"Kansas State Veterinary Diagnostic Laboratory, Kansas State University, Manhattan, Kansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjen","family":"Companjen","sequence":"additional","affiliation":[{"name":"Crucell Holland B.V., Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander B. H.","family":"Bakker","sequence":"additional","affiliation":[{"name":"Crucell Holland B.V., Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfred E.","family":"Marissen","sequence":"additional","affiliation":[{"name":"Crucell Holland B.V., Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"von Eyben","sequence":"additional","affiliation":[{"name":"Crucell Holland B.V., Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerrit Jan","family":"Weverling","sequence":"additional","affiliation":[{"name":"Crucell Holland B.V., Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathleen","family":"Hanlon","sequence":"additional","affiliation":[{"name":"Kansas State Veterinary Diagnostic Laboratory, Kansas State University, Manhattan, Kansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap","family":"Goudsmit","sequence":"additional","affiliation":[{"name":"Crucell Holland B.V., Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.14.9062-9068.2005"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1016\/j.vaccine.2008.08.050","article-title":"First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity","volume":"26","author":"Bakker AB","year":"2008","unstructured":"BakkerAB . 2008. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 26:5922\u20135927.","journal-title":"Vaccine"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"8647","DOI":"10.1016\/j.vaccine.2007.10.004","article-title":"An important date in rabies history","volume":"25","author":"Dodet B","year":"2007","unstructured":"DodetB. 2007. An important date in rabies history. Vaccine 25:8647\u20138650.","journal-title":"Vaccine"},{"key":"e_1_3_2_5_2","volume-title":"Bioanalytical method validation","author":"FDA","year":"2001","unstructured":"FDA. 2001. Guidance for industry. Bioanalytical method validation. Food and Drug Administration, Rockville, MD."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1086\/500470","article-title":"Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin","volume":"193","author":"Goudsmit J","year":"2006","unstructured":"GoudsmitJ . 2006. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J. Infect. Dis. 193:796\u2013801.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_7_2","first-page":"369","volume-title":"Laboratory techniques in rabies","author":"Habel K","year":"1996","unstructured":"HabelK. 1996. Habel test for potency, p 369\u2013373. In MeslinFX KaplanMM KoprowskiH (ed), Laboratory techniques in rabies, 4th ed. World Health Organization, Geneva, Switzerland.","edition":"4"},{"key":"e_1_3_2_8_2","unstructured":"ICH. 2005. Validation of analytical procedures: text and methodology Q2(R1). ICH Geneva Switzerland."},{"key":"e_1_3_2_9_2","first-page":"S37","article-title":"Assessment of bias with emphasis on method comparison","volume":"29","author":"Johnson R","year":"2008","unstructured":"JohnsonR. 2008. Assessment of bias with emphasis on method comparison. Clin. Biochem. Rev. 29(Suppl 1):S37\u2013S42.","journal-title":"Clin. Biochem. Rev."},{"key":"e_1_3_2_10_2","first-page":"1","article-title":"Human rabies prevention\u2014United States, 2008: recommendations of the Advisory Committee on Immunization Practices","volume":"57","author":"Manning SE","year":"2008","unstructured":"ManningSE . 2008. Human rabies prevention\u2014United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep. 57:1\u201328.","journal-title":"MMWR Recomm. Rep."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.8.4672-4678.2005"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000595"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1056\/NEJMcp042140","article-title":"Clinical practice. Prophylaxis against rabies","volume":"351","author":"Rupprecht CE","year":"2004","unstructured":"RupprechtCE GibbonsRV. 2004. Clinical practice. Prophylaxis against rabies. N. Engl. J. Med. 351:2626\u20132635.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_14_2","first-page":"535","article-title":"A rapid reproducible test for determining rabies neutralizing antibody","volume":"48","author":"Smith JS","year":"1973","unstructured":"SmithJS YagerPA BaerGM. 1973. A rapid reproducible test for determining rabies neutralizing antibody. Bull. World Health Organ. 48:535\u2013541.","journal-title":"Bull. World Health Organ."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9291-7"},{"key":"e_1_3_2_16_2","unstructured":"WHO. 2011. The immunological basis for immunization series module 17: rabies. World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1016\/j.vaccine.2010.08.082","article-title":"Rabies vaccines: WHO position paper\u2014recommendations","volume":"28","author":"WHO","year":"2010","unstructured":"WHO. 2010. Rabies vaccines: WHO position paper\u2014recommendations. Vaccine 28:7140\u20137142.","journal-title":"Vaccine"},{"key":"e_1_3_2_18_2","unstructured":"WHO. 2002. WHO consultation on a rabies monoclonal antibody cocktail for rabies post exposure treatment. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/rabies\/vaccines\/en\/mabs_final_report.pdf."},{"key":"e_1_3_2_19_2","unstructured":"WHO. 1997. WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. WHO\/EMC\/ZOO\/96.6. World Health Organization Geneva Switzerland. http:\/\/whqlibdoc.who.int\/hq\/1996\/WHO_EMC_ZOO_96.6.pdf."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.06179-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.06179-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T13:57:37Z","timestamp":1645451857000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.06179-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1128\/AAC.06179-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.06179-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"2011-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-04-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}